Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets ...
Forbes

What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
NJBIZ

Bayer, Recursion collaborate on digital drug discovery for fibrotic diseases

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...
NextBigFuture

Vicarious developing machine learning using Recursive Cortical Network

Technology Review – Your eyes work with your brain to teach you about the world. You learn to recognize objects, people, and places, and you learn to imagine new things. A startup called Vicarious ...